Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock

Key Points

• CEO Helen Torley of Halozyme Therapeutics sold $1,380,600 worth of stock, a transaction reflecting a 2.65% decrease in her ownership.
• The company's shares experienced a 3.8% drop in trading, and currently have a market capitalization of $8.07 billion.
• Halozyme's recent earnings report showed a 40.8% year-over-year revenue increase, with earnings per share of $1.54, surpassing expectations.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $69.03, for a total value of $1,380,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Wednesday, October 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $74.44, for a total value of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Trading Down 3.8%

Shares of NASDAQ HALO traded down $2.71 during trading hours on Friday, hitting $68.98. The company's stock had a trading volume of 2,656,731 shares, compared to its average volume of 1,995,680. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The stock has a market cap of $8.07 billion, a price-to-earnings ratio of 15.78, a P/E/G ratio of 0.41 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The business has a 50-day simple moving average of $70.23 and a 200-day simple moving average of $61.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Large investors have recently made changes to their positions in the business. Wealth Preservation Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth approximately $33,000. Bessemer Group Inc. raised its holdings in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $32,000. Finally, Employees Retirement System of Texas purchased a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $34,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on HALO shares. Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. HC Wainwright lifted their price objective on Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $70.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.